Decoding the Metabolic Trio: GLP-1, GIP and Glucagon Research

GLP‑1, GIP and glucagon receptors together represent the most actively investigated hormone system in metabolic science today, and their interplay is reshaping how researchers think about energy balance and glucose control.

What researchers are exploring

Scientists are asking a series of focused questions that cut across basic biology, disease modelling and potential therapeutic concepts. Each question reflects a gap in our understanding and a possible route to new insights.

• Can selective activation of the GLP‑1 receptor enhance insulin secretion without triggering excessive low blood‑sugar episodes?
• Does stimulating the GIP receptor improve nutrient‑driven fat storage in a way that could protect against obesity‑related inflammation?
• What metabolic outcomes arise when both GLP‑1 and glucagon receptors are engaged simultaneously, and does this dual signalling improve energy expenditure?
• Are there synergistic benefits when a single peptide engages all three receptors (GLP‑1, GIP and glucagon) compared with activating each one separately?
• How do genetic variations in these receptors influence cellular responses, and could they explain differences seen across animal strains or human populations?

How it may work

All three receptors belong to the family of G‑protein‑coupled receptors (GPCRs), membrane proteins that translate an external signal into an internal cellular response. When a peptide binds to GLP‑1 or GIP receptors, the receptor activates the enzyme adenylate cyclase, raising cyclic AMP levels and prompting insulin‑producing β‑cells to release more insulin. In contrast, glucagon receptor activation stimulates a separate signalling cascade that raises blood glucose by promoting hepatic glucose production and increasing lipolysis (fat breakdown). Researchers hypothesise that a carefully balanced activation of the three pathways could tip the metabolic scale toward improved glucose handling while also boosting calorie burning, but the exact wiring of these signals remains under investigation.

What the evidence says

Cellular and in‑vitro studies

In cultured pancreatic beta‑cell lines, GLP‑1 receptor agonists increase insulin gene expression and secretion when glucose is present, confirming the classic potentiation effect. Parallel experiments with adipocyte (fat‑cell) cultures show that GIP receptor activation can enhance lipid uptake, but only under certain nutrient conditions, suggesting a context‑dependent role. Researchers using hepatocyte (liver‑cell) models report that glucagon receptor engagement raises enzymes involved in glucose output, mirroring the hormone’s natural function. When a single synthetic peptide that can bind all three receptors is added to a mixed cell system, investigators observe a modest increase in both insulin release and fatty‑acid oxidation, hinting at a coordinated response.

Animal models

Rodent studies provide the next layer of evidence. In diet‑induced obesity mice, chronic GLP‑1 receptor activation leads to lower fasting blood glucose and modest weight stabilization, while GIP receptor activation alone does not consistently affect body weight. When glucagon receptors are stimulated, mice show a rise in energy expenditure measured by indirect calorimetry, but also a temporary increase in blood glucose. Importantly, animals given a tri‑agonist peptide that hits all three receptors display a combined pattern: modestly lower glucose, a small but measurable rise in metabolic rate, and no dramatic changes in food intake. These findings suggest additive, but not simply additive, effects across the three pathways.

Human investigations

Human data are still limited. Small early‑phase studies have examined GLP‑1 receptor agonists as single agents, showing the expected rise in insulin after meals. Separate trials with GIP‑focused compounds have produced mixed signals, with some reporting enhanced post‑prandial insulin and others showing little effect. Glucagon receptor agonists have been explored mainly to understand their impact on metabolic rate, and results indicate a slight increase in energy expenditure but also a rise in circulating glucose. To date, no peer‑reviewed study has evaluated a single peptide that simultaneously activates all three receptors in people, leaving a clear gap between animal findings and human translation.

How it compares to other peptide agonists

The most widely studied single‑receptor agents are GLP‑1 analogues such as semaglutide, which have a well‑characterised effect on insulin secretion and appetite control. GIP‑centric compounds like tirzepatide add a second target, and early research suggests they may broaden metabolic benefits, yet they still fall short of directly engaging glucagon pathways. By contrast, tri‑agonist designs aim to capture the glucose‑lowering power of GLP‑1, the nutrient‑sensing role of GIP, and the energy‑burning signal of glucagon in one molecule. This integrated approach differentiates them from the more incremental dual‑agonists currently in clinical pipelines.

What we still don\'t know

Key uncertainties remain. The optimal balance of activation across the three receptors has not been defined, and excessive glucagon signalling could negate glucose‑lowering benefits. Long‑term safety data, especially regarding pancreatic or liver stress, are absent because most studies have been short‑term animal experiments. Delivery methods that preserve peptide stability while reaching the intended targets are still under development, and it is unclear how genetic differences among individuals might modulate response. Until these gaps are addressed, conclusions about therapeutic potential remain speculative.

Questions worth asking

• How robust is the human evidence for each individual receptor compared with the pre‑clinical data for the combined tri‑agonist?
• What biomarkers would reliably indicate a balanced activation of GLP‑1, GIP and glucagon pathways in a research setting?
• If a tri‑agonist proves safe in animals, what additional studies are needed to assess its relevance to human metabolism?
• How might individual genetic variation in these receptors influence experimental outcomes, and should researchers screen for such variants?

Compliance reminder

The information provided here is for research and educational purposes only. The peptides discussed are not listed on the Australian Register of Therapeutic Goods (ARTG) and must not be used for human or animal consumption.